MEDX Xelerator

VeinWay is a medical device company focused on developing innovative solutions for the treatment of chronic venous occlusions caused by blockage or disease. The firm's primary offering is a specialized catheter designed to recanalize obstructed veins, providing physicians with a dedicated tool to navigate and clear complicated blockages. By facilitating the restoration of blood flow to the heart, VeinWay aims to transform the management of chronic venous disease and improve patient outcomes. The company's technology not only enables medical professionals to cross previously un-crossable obstructions but also aims to reduce the time required for such procedures.

Exero Medical is a medical device manufacturing company headquartered in Or Yehuda, Israel, founded in 2018. The company specializes in developing a biodegradable wireless sensor aimed at the early detection of anastomotic leaks following gastrointestinal surgery. This innovative device enhances patient recovery by allowing healthcare professionals to monitor the anastomosis area in real-time, which facilitates timely intervention and can lead to shorter hospitalization periods. By providing critical data that enables preventive actions, Exero Medical's technology seeks to reduce complications associated with surgical procedures, ultimately improving patient outcomes.

Append Medical is a medical technology company focused on developing an innovative transcatheter Left Atrial Appendage (LAA) closure system aimed at preventing strokes by reducing the risk of blood clots traveling to the brain. The company’s approach involves a uniquely designed system that eliminates the LAA through tissue invagination and suture closure, providing a simplified alternative to traditional implant-based LAA closures. This method is intended to minimize the presence of foreign materials at the closure site, thereby reducing device-related thromboembolism risks. Currently in the pre-clinical in-vivo trial phase, Append Medical operates within a market projected to grow significantly, with estimates suggesting the LAA closure market could reach $25 billion in the coming years. The company is also affiliated with MEDX Xelerator, a medtech incubator supported by several prominent organizations.

Swift Duct develops a navigational tool for the ERCP procedure, which minimizes the risk of infections in the pancreas.

Synchrony Medical is a clinical stage medical device company focused on the development of LibAirty, an advanced airway clearance system intended for home use. This innovative device aims to assist patients with chronic lung diseases, such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), in maintaining clear lungs through efficient daily treatments. By enabling remote monitoring and personalized respiratory therapy, Synchrony Medical's solution offers patients a tailored approach to managing their condition, enhancing lung function, and facilitating effective airway clearance.

Dimoveo Medical focuses on developing innovative disinfection technologies aimed at enhancing the safety of medical implants without necessitating their removal from the body. The company’s ultrasound-based system employs ultrasound-accelerated nanoparticles, which are designed to effectively clean in-body surfaces and implants. This advanced technology facilitates the cleaning of implants at high velocities, ensuring that they remain undisturbed while significantly reducing the risk of infection and the need for revision surgeries. Primarily targeting patients undergoing orthopedic procedures, such as knee replacements, Dimoveo Medical's solutions aim to improve patient outcomes and overall surgical protocols.

PatenSee is a clinical-stage medical device company founded in 2019 in Or Yehuda, Central, by Gal Goshen. The company specializes in a contactless surveillance system aimed at detecting early signs of asymptomatic vascular stenosis in hemodialysis patients. Utilizing advanced multi-modal imaging technologies and machine learning, PatenSee's system is designed to seamlessly integrate into clinical workflows. This technology enables healthcare teams to identify early indications of vascular access stenosis, facilitating preventative and cost-effective interventions. By safeguarding the vascular access crucial for hemodialysis, PatenSee aims to enhance patient care and ultimately improve life expectancy for individuals undergoing this treatment.